Simcere expands national reimbursement coverage for key cancer drugs

Simcere Pharmaceutical Group Limited announced that ENZESHU® (Suvemcitug for injection) has been officially included in China's "Drugs Catalogue for the National Basic Medical Insurance, Work-related Injury Insurance and Maternity Insurance (2025)." This inclusion, effective January 1, 2026, follows the drug's approval for marketing in China on June 30, 2025. ENZESHU® is indicated for the treatment of recurrent ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.

In addition, ENDOSTAR® (Recombinant Human Endostatin for Injection) successfully completed its renewal under the National Reimbursement Drug List (NRDL). Endostar®, China's first anti-angiogenic targeted therapy, has been listed in the NRDL since 2017 and is a cornerstone treatment for advanced non-small cell lung cancer.

This development positions Simcere, an innovation and R&D-driven pharmaceutical company, to broaden the reach of its key therapies, aligning with its mission to provide future medicines for patients today. The company focuses on neuroscience, anti-oncology, autoimmune, and anti-infection therapeutic areas.